Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs

Novo Nordisk A/S187 enrolled

Overview

This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of repaglinide and metformin combination therapy in Chinese subjects with type 2 diabetes inadequately controlled with OAD (oral anti-diabetic drugs).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

187

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

repaglinideDRUG

metforminDRUG

Eligibility

Sex: ALLMin age: 35 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes for at least 12 weeks * HbA1c: 8.0-10.0% * Current treatment with OAD on monotheray or OAD on combination therapy * Body mass index (BMI): 21.0-35.0 kg/m2 Exclusion Criteria: * Known or suspected allergy to trial product(s) or related products * Recurrent major hypoglycaemia as judged by the Investigator * Uncontrolled hypertension * Any other significant condition or concomitant disease such as endocrine, cardiac, neurological, malignant or other pancreatic disease as judged by the Investigator

Locations (1)

Unnamed facility

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

HbA1c

Time frame: after 18 weeks of treatment

Secondary Outcomes

Post Prandial Plasma Glucose

Fasting Plasma Glucose (FPG)

Safety profile

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.